BioCardia


	BioCardia is a biotherapeutic platform and product company based on fully developed medical device technologies.

CORE BUSINESSES

BioCardia is engaged in two core businesses:

Helix Biotherapeutic Delivery offers a catheter system for the local delivery of cells, gene, and protein therapeutics to the heart.

Morph Access Innovations develops advanced catheter products for interventional medicine.

HELIX NEWS

August 14, 2009
University of Miami announces successful completion of safety phase of autologous stem cells in Transendocardial Autologous Cells in Heart Failure Trial (TAC-HFT); sixty patient randomized portion of trial has been initiated

March 10, 2009
TABMMI Heart Failure Stem Cell Clinical Trial Results Presented; Improvements Sustained at Three Year Follow-up

May 2009
Morph® AccessPro™ Receives FDA Clearance

March 2009
A new article has been published in the March 2009 issue of Endovascular Today entitled “Celiac Artery Stenting.”